Transforming Care Within and Beyond the NICU

Tellus Therapeutics was founded on a singular mission: to bring hope and healing to the most vulnerable patients – premature infants facing life-altering brain and gut injuries with no treatment options.

By pioneering the first myelination therapy for neonatal white matter injury, we’re not just addressing a critical gap in NICU care – we’re establishing proof-of-concept for a regenerative medicine platform that could transform how we treat diseases of myelination and inflammation from early infancy to adulthood.

At Tellus, we believe that by starting in the NICU, where the need is greatest, we can alleviate the suffering of thousands of families in immediate and dire need, and ultimately deliver significant advances in neuro-regenerative medicine.